$ACAD (ACADIA PHARMACEUTICALS) — 8-K: Acadia reaches proposed settlement of stockholder derivative matters

Acadia Pharmaceuticals, Inc. has entered into a proposed settlement of stockholder derivative litigation and related Section 220 demands. The settlement requires court approval, with a hearing scheduled for January 13, 2027, before the Honorable William Q. Hayes in the United States District Court for the Southern District of California. Current Acadia stockholders as of July 9, 2026, will be bound by the settlement if approved. The derivative action is not a class action, and no common fund or monetary payment to stockholders is provided.

Acadia Pharmaceuticals, Inc. has entered into a proposed settlement of stockholder derivative litigation and related Section 220 demands. The settlement requires court approval, with a hearing schedul